• Sul Lee, Hyun Joo Lee, Kyung Un Choi, Byung Su Kwon, Dong Soo Suh, Dae Hoon Jeong, Geun Joo Kim, Tae Hwa Lee, Hyun-Jin Roh, and Ki Hyung Kim.
• Department of Obstetrics and Gynecology, School of Medicine, Pusan National University, Busan, South Korea.
• J Res Med Sci. 2020 Jan 1; 25: 47.

BackgroundSerous adenocarcinoma of the uterine cervix is an extremely rare variant of cervical adenocarcinoma. This study aimed to evaluate the clinicopathological and molecular features and outcomes of serous adenocarcinoma of the uterine cervix (SACC).Materials And MethodsThis was a retrospective study conducted based on the clinical and pathological data of seven patients diagnosed with SACC after hysterectomy, who were evaluated at the gynecologic oncologic centers between 2010 and 2019.ResultsFive cases were diagnosed at Stage IB and two at Stage IV. All patients underwent radical hysterectomy with bilateral salpingo-oophorectomy and subsequently received postoperative radiotherapy or chemotherapy. One patient showed persistent disease, and two patients suffered recurrence. Immunohistochemical study showed that three (43%) of the seven patients were positive for p53, and among these three patients, two with diffuse strong p53 expression experienced an aggressive course with recurrences at pelvic lymph nodes, lung, and brain.ConclusionHigh p53 expression and advanced stage may be associated with poorer clinical outcomes in SACC, which suggest that immunohistochemistry may contribute to the prediction of prognosis.Copyright: © 2020 Journal of Research in Medical Sciences.

3 keywords...

hide…